Skip to Main Content



This site is undergoing maintenance. If you are in the process of entering information, please complete it in the next few minutes and then log off, to ensure that you are not interrupted. If you were about to start entering details, please wait until this message is removed. You may continue to browse content on the site during the upgrade if you wish. We apologize for any inconvenience this may cause.

The C9 (C9ORF72) Breakthrough

What is it?

C9ORF72 is the location of a gene abnormality--discovered by two independent research teams funded by The ALS Association--that accounts for a significant percentage of cases of ALS.

Who are the researchers?

The teams were led by Bryan Traynor, M.D., Laboratory of Neurogenetics, National Institute on Aging, and Rosa Rademakers, Ph.D., Mayo Clinic, Jacksonville, FL.

What is the significance of the breakthrough?

According to Lucie Bruijn, Ph.D., Chief Scientist for The ALS Association, the key implications of this breakthrough are:

Learn more about ALS research.




All content and works posted on this website are owned and copyrighted by The ALS Association. ©2019
Contact the Webmaster